Introduction
Chronic kidney disease (CKD) is associated with high overall and cardiovascular mortality that increases as kidney function decreases [1] [2] [3] . Up to 45% of pre-dialysis CKD patients may die before reaching end-stage kidney disease (ESKD), with cardiovascular disease being the leading cause of death [4] . The reasons for the high cardiovascular mortality are not fully understood, but vascular calcification (a common complication of CKD) may be an important risk factor based on the association of aortic calcification with increased cardiovascular morbidity and mortality in the general [5] [6] [7] and haemodialysis [8] populations. Pre-dialysis CKD patients have advanced vascular calcification compared to diabetic patients and healthy subjects [9, 10] , and there is an association between moderate CKD and coronary artery calcification (CAC) [11] [12] [13] [14] ; however, vascular calcification in pre-dialysis CKD is not fully understood.
In this study, we used non-contrast computed tomography (CT) to evaluate the abdominal aortic calcification index (ACI) [15, 16] as a semi-quantitative measure of aortic calcification. The study was performed in 101 adult Japanese patients with pre-dialysis CKD stages 3 to 5 to investigate the prevalence, extent, predictors and prognostic significance of abdominal aortic calcification in this patient population.
Materials and methods

Subjects
The subjects were patients who attended the Department of Nephrology, Musashino Red Cross Hospital and met the following inclusion criteria: (i) age >18years old, (ii) CKD stages 3 to 5 (not requiring kidney replacement therapy), (iii) no history of cardiovascular disease, stroke, rapidly progressive kidney disease or extremity amputation, and (iv) no malignancy. Diagnosis and classification of CKD were based on criteria from the Clinical Practice Guidelines for Chronic Kidney Disease from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative [17] . Kidney function was evaluated by the estimated glomerular filtration rate (e-GFR) calculated using the equation for Japanese subjects recommended by the Japanese Society of Nephrology: e-GFR (mL/min/1.73m
2 ) = 194×SCr −1.094 ×Age −0.287 ×0.739 (if female) [18, 19] . The study was started in April 2004, and patient recruitment was closed in October 2004. The subjects were followed for a mean period of 48 ± 12 (SD) months. Baseline data and outcomes were obtained from hospital records. Informed consent was obtained from all patients, and the study was approved by the Institutional Ethical Committee.
Laboratory data and clinical characteristics
Haemoglobin, serum creatinine, albumin, calcium, phosphorus, C-reactive protein (CRP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL) and triglycerides were measured as part of routine follow-up. The mean values of three measurements obtained over ∼6months prior to the CT scan were used for analysis. Total serum calcium was adjusted if serum albumin was <4g/dL to better reflect the free calcium, using the formula proposed by the US Bone Metabolism Association [20] : corrected total calcium (mg/dL)=total calcium (mg/dL)+0.8×[4.0 − serum albumin (g/dL)]. Intact parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (Vit-D) were measured once at the time of the CT scan. Weight and height were measured for calculating body mass index (BMI). Oral medications including calcium carbonate , multiply by 0.01667; total, LDL and HDL cholesterol in mg/dL to mmol/L, multiply by 0.02586; triglycerides in mg/dL to mmol/L, multiply by 0.01129; Haemoglobin in g/dL to g/L, multiply by 10; albumin in g/dL to g/L, multiply by 10; serum albumin-corrected calcium in mg/ dL to mmol/L, multiply by 0.2495; phosphorus in mg/dL to mmol/L, multiply by 0.3229; intact PTH in pg/mL to ng/L, multiply by 1; 1,25-dihydroxy vitamin D in pg/mL to pmol/L, multiply by 2.6. Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; CKD, chronic kidney disease; e-GFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone. Abdominal aortic calcification in chronic kidney disease(phosphate binder), vitamin D, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and statins were recorded. Blood pressure was measured in the sitting position at regular hospital visits, with the mean of three measurements over ∼6months prior to the CT scan used for analysis.
Measurement of the abdominal aortic calcification index
A non-contrast CT scan of the abdominal aorta was performed with a LightSpeed Plus instrument (GE Healthcare, Waukesha, WI). The scan parameters were 120 kVp, 100 mAs and a 1-s rotation speed. The slice thickness was 2.5mm. Image data were transferred to a workstation, and 10 slices of 10-mm thickness were reconstructed just above the bifurcation of the common iliac arteries. Calcification was considered to be present if an area ≥1mm 2 displayed a density ≥130 Hounsfield units. The cross-section of the abdominal aorta on each slice was divided into 12 segments radially. A segment containing an aortic wall with calcification in any section was defined as having aortic calcification. The number of calcified segments was counted in each slice and divided by 12. The values thus obtained for the 10 slices were added together, divided by 10 (the number of slices inspected) and then multiplied by 100 to express the result as a percentage [15, 16] : ACI (%)=(total score for calcification in all slices) / (12 [number of segments in each slice] × 10 [number of slices]) × 100. The ACI was used as a marker of the extent of aortic calcification. The recorded ACI was the mean of measurements made by two independent observers (r=0.97, P<0.001) who were blinded to the clinical data.
Statistical analysis
Data are expressed as means±SD (for normally distributed data), median and interquartile range (IQR) or count and percentage. Differences between two groups were evaluated by Student t-test, MannWhitney U-test or Kruskal-Wallis test. Comparisons among three groups were assessed by one-way analysis of variance, with KruskalWallis test or Steel-Dwass post hoc test used for data that were not normally distributed, and Tukey test used for normally distributed data. Predictive factors for aortic calcification were first examined by univariate logistic regression analysis, and variables with a significant association (P<0.10) were included in multivariate logistic regression analysis (stepwise backward elimination). Survival curves were estimated by the Kaplan-Meier method and evaluated using a Log-rank test. Predictive variables for outcomes were first examined using univariate Cox proportional hazards analysis, and variables with a significant association (P < 0.10) were used in a multivariate Cox proportional hazards model. P < 0.05 was considered significant. Statistical analysis was performed using SPSS for Windows, v.16 (SPSS Inc., Chicago, IL, USA). Table 2 . Clinical characteristics of subjects with (ACI>0%) and without (ACI=0%) aortic calcification (left column) and with high (ACI ≥ 20%) and low (ACI < 20%) aortic calcification (right column) 
Results
Characteristics of the subjects
The 101 patients (64 males, 37 females) had a mean age of 66.6 ± 11.3years old and a mean e-GFR of 20.3 ± 14.0 mL/min/1.73m 2 . Eighteen had CKD stage 3 (e-GFR, 30-59mL/min/1.73m
2 ), 29 had CKD stage 4 (e-GFR, 15-29 mL/min/1.73m
2 ) and 54 had CKD stage 5 (e-GFR, < 15 mL/min/1.73m 2 ). None had received kidney replacement therapy. The primary kidney diseases were chronic glomerulonephritis (39%), diabetic nephropathy (29%), nephrosclerosis (18%) and others (14%). All patients were under the care of nephrologists and were on a low protein diet (0.8g/kg body weight/day). However, the number of patients who practiced this diet was unknown since data for estimation of protein intake, such as urine nitrogen excretion [21, 22] , were unavailable. Clinical characteristics and laboratory data are summarized in Table 1 . Age, gender and BMI did not differ significantly among the three CKD stages. Patients with a higher CKD stage had higher creatinine, phosphorus, calcium and phosphorus products, intact PTH, CRP (not significant) and systolic blood pressure (not significant) and lower e-GFR, Vit-D, TC, LDL, HDL (not significant), serum albumin-corrected calcium, albumin (not significant) and haemoglobin. Diabetic nephropathy was significantly more frequent in patients with CKD stage 5 (37%) compared to stage 3 (11%). Only 12 patients were taking calcium carbonate, reflecting the well-controlled serum phosphorus levels.
Prevalence and severity of abdominal aortic calcification
A total of 82% (82/101) of the subjects had abdominal aortic calcification (ACI > 0), including 50% (9/18) in stage 3, 83% (24/29) in stage 4 and 91% (49/54) in stage 5. There were significant differences in prevalence among the three CKD groups (Table 2) . Thus, patients with a higher CKD stage had a higher prevalence of abdominal aortic calcification. The patients with aortic calcification were older; had significantly higher systolic blood pressure, serum phosphorus and intact PTH; more frequent diabetic nephropathy as the primary disease; a higher prevalence of diabetes; and significantly lower e-GFR, haemoglobin, serum albumin and Vit-D compared to patients without aortic calcification ( Table 2 ).
The To identify predictors of abdominal aortic calcification, multivariate logistic regression analysis was performed using the presence or absence of calcification (ACI>0 or= 0) as the dependent variable and nine variables (Table 2 ) with a significant association with abdominal aortic calcification (P<0.10) in univariate analysis as independent variables (Table 3) . To identify predictors of high abdominal aortic calcification, we divided the cohort into patients with ACI ≥ 20% (n=44) and <20% (n=57), based on the median ACI of 16.7%. The median ACI values in these sub-groups were 42.7% (IQR, 28.1-55.5%) and 8.3% (0.0-14.2%), respectively (P < 0.001). Multivariate logistic regression analysis was performed using the presence or absence of high calcification (ACI ≥ 20% or <20%) as the dependent variable and 10 variables selected as above as independent variables (Table 4) . Older age, presence of diabetes and decreased e-GFR were found to be independent predictors of both the presence (ACI>0) and extent (ACI ≥ 20%) of abdominal aortic calcification.
Correlation between ACI and e-GFR
ACI was negatively correlated with e-GFR in single regression analysis (r=−0.30, P=0.002) (Figure 2 ). The correlation was still significant (r=−0.24, P=0.015) after adjustment for age but not after adjustment for age and presence of diabetes (r=−0.18, P=0.092).
Outcomes and prognosis of the subjects
During the follow-up period of 48 ± 12months, 50 patients [n=0 (0%), 10 (34%) and 40 (74%) for CKD stages 3, 4 and 5 at baseline, respectively] started dialysis therapy due to progression to ESKD. Of these 50 patients, two received peritoneal dialysis and 48 received haemodialysis. None underwent kidney transplantation. The mean intervals from CT scanning to induction of dialysis therapy were 32.9 ± 15.5 and 15.8 ± 11.9months for CKD stages 4 and 5, respectively (P=0.007). Eight patients (n=0, 1 and 7 for CKD stages 3, 4 and 5, respectively) died. Four (n = 1 and 3 for CKD stages 4 and 5, respectively) died of cardiovascular diseases, including ischaemic heart disease (n = 3) and congestive heart failure (n = 1). Three of these deaths occurred while the patient was under dialysis therapy. There were four non-cardiovascular deaths due to infectious diseases (n = 2) and cancer (n = 2); all four patients had CKD stage 5 at baseline and died under dialysis therapy.
De novo cardiovascular events occurred in 22 patients (n = 1, 6 and 15 for CKD stages 3, 4 and 5, respectively): in 10 patients (n = 1, 4 and 5) before and 12 patients (n=0, 2 and 10) after induction of dialysis therapy. The 22 cardiovascular events included ischaemic heart disease (n = 11), congestive heart failure (n=5), stroke (n=4), peripheral vascular disease (n = 1) and sudden death (n = 1). The mean intervals from CT scanning to the cardiovascular event were 46 (one patient), 38.2 ± 9.7 and 27.1 ± 14.8months for CKD stages 3, 4 and 5, respectively (stage 4 vs stage 5, P=0.112). The mean interval from induction of dialysis to the occurrence of a de novo cardiovascular event in 12 patients was 21.9 ± 13.2months.
Predictors of de novo cardiovascular events
The small number of deaths during the follow-up period did not permit evaluation of overall or cardiovascular mortality. Thus, we evaluated the incidence of de novo cardiovascular events. Since only one patient with CKD stage 3 had a cardiovascular event, the analysis was only performed in patients with CKD stages 4 and 5 (n=83) . To analyze the association of vascular calcification with de novo cardiovascular events, the pa- tients with CKD stages 4 and 5 were divided into those with ACI ≥ 20% (n=42) and <20% (n=41). The median ACI values in these groups were 41.0% (IQR, 28.0-55.2%) and 10.0% (4.3-14.4%), respectively (P < 0.001). Patients with ACI ≥ 20% had more de novo cardiovascular events compared to those with ACI < 20% (35.7% vs 14.6%, P=0.027). Unadjusted cardiovascular event-free survival curves for patients with ACI ≥ 20% and <20% are shown in Figure 3 (P =0.007 by Log-rank test). In univariate Cox proportional hazards analysis, ACI ≥ 20% and the presence of diabetes were significantly associated with de novo cardiovascular events, whereas factors including age and e-GFR were not (Table 5 ). In a multivariate Cox proportional hazards model using significant variables (P<0.10) from the univariate analysis, ACI ≥ 20% and presence of diabetes were identified as independent predictors of de novo cardiovascular events (Table 5) .
Effect of abdominal aortic calcification on progression to ESKD
Dialysis-free survival did not differ significantly between patients in CKD stages 4 and 5 with ACI ≥ 20% and <20% (P=0.171 by Log-rank test). ACI ≥ 20% was not significantly associated with progression to ESKD [hazard ratio (HR), 1.47; 95% confidence interval (95% CI) 0.84-2.58; P = 0.180] in univariate Cox proportional hazards analysis and remained insignificant after adjustment for age, presence of diabetes and e-GFR (HR, 1.31; 95% CI 0.75-2.49; P = 0.311).
Discussion
A high prevalence and extent of CAC have been found in CT studies of patients with pre-dialysis CKD, with a significant association between decreased GFR and CAC [11] [12] [13] [14] . In contrast, aortic calcification in pre-dialysis CKD has been less well studied. Abdominal aortic calcification has been associated with an increased risk of cardiovascular morbidity and mortality in the general [5] [6] [7] and haemodialysis [8] populations, and aortic calcification has been correlated with findings in coronary arteries, which in turn predict all-cause mortality [23, 24] . Thus, we used the ACI for semi-quantitative assessment of aortic calcification. The section of the aorta chosen for measuring the ACI is suitable for evaluation of the severity of vascular calcification because the site is associated with turbulent flow and is susceptible to development of atheroma. The chosen site is also simple to investigate radiologically since it is in a straight part of the aorta and is vertical to the transverse plane. Abdominal aortic calcification in dialysis patients has been examined using this method [15, 16, [25] [26] [27] , but this is the first study in a pre-dialysis CKD population.
Abdominal aortic calcification was present in 82% of our subjects, consistent with the rate of 90% reported in CKD patients with a mean GFR of 35 mL/min and a mean age of 64years old [28] , and far exceeding the rates of 27-57% found in the general elderly population [10, 29, 30] . We also found that a higher CKD stage was associated with a higher prevalence of abdominal aortic calcification and that decreased GFR was an independent risk factor. The median ACI of 16.7% was lower than those of 25-61% found previously for haemodialysis patients [15, 16, [25] [26] [27] ; there are no available data for the general population. Patients with CKD stages 4 and 5 had significantly higher ACI values compared to those with stage 3, and decreased GFR was an independent risk factor for high abdominal aortic calcification (ACI ≥ 20%). The literature for CAC [11] [12] [13] [14] and our findings suggest a strict link between CKD and vascular calcification. Loss of kidney function may disturb the interaction of inducers and inhibitors of vascular calcification, which is now recognized to be an actively regulated process similar to that for bone formation [31] . Additionally, an older age and diabetes, which are well-known atherosclerotic risk factors, were also found to be important risk factors for abdominal aortic calcification. In the process of vascular calcification in pre-dialysis CKD, there may be a complex interaction between traditional atherosclerotic factors and CKD-specific factors, which may have more influence with progression of the CKD stage. Raised systolic blood pressure showed a tendency for an association with calcification, but it is unclear from our data whether this is a cause or a consequence. CKD-MBD-related factors such as serum calcium, phosphorus and PTH are thought to be strongly associated with the severity of vascular calcification in dialysis patients [32, 33] . However, these relationships in pre-dialysis CKD are not well understood. In the present study, CKD-MBD-related factors were not independent risk factors for abdominal aortic calcification, although these factors showed tendencies for associations in univariate analysis. However, recent studies in pre-dialysis CKD patients have demonstrated a significant relationship of serum phosphorus with vascular calcification [34, 35] . Adeney et al. [34] showed that higher serum phosphorus (even within the normal laboratory range) was associated with a greater prevalence of calcification of the coronary artery and thoracic aorta in pre-dialysis CKD patients mainly of stage 3, and Russo et al. [35] found an association of higher serum phosphorus with progression of CAC. Therefore, the well-controlled serum calcium and phosphorus levels in our patients may have attenuated the effects of CKD-MBD-related factors. Alternatively, the relatively small sample size or measurements of steady-state serum electrolytes for only a few months may have limited our ability to find significant relationships between vascular calcification and CKD-MBD-related factors. Further investigation in prospective studies with larger sample sizes and more confounding CKD-MBD-related factors such as FGF-23 [36] is needed to address this issue.
This study shows the impact of high abdominal aortic calcification and diabetes on de novo cardiovascular events in pre-dialysis CKD, suggesting that the significant association of decreased GFR with vascular calcification may be one reason for the high cardiovascular mortality in pre-dialysis CKD. In contrast, a direct association of decreased e-GFR with cardiovascular events was not found. This may be because of the limitation of the analysis to patients with CKD stages 4 and 5, based on the evidence that a higher CKD stage is associated with an increased risk of cardiovascular events [3] . In addition, an older age was not independently associated with de novo cardiovascular events. Interestingly, a recent study in kidney transplantation recipients [37] with a history of kidney insufficiency also showed that aortic calcification and diabetes are major independent risk factors for cardiovascular events. Of the events, 57% occurred after induction of dialysis therapy, but we did not evaluate the effect of dialysis therapy. Additionally, we found that a high level of abdominal aortic calcification did not predict earlier progression to ESKD.
The association between vascular calcification and progression of CKD has not been evaluated previously, and further evaluation of the rate of decline of GFR and major predictors such as proteinuria [38] is needed to understand this issue better.
There are several limitations in the study. Firstly, because vascular calcification was not followed up prospectively, we cannot say that ACI progressed as GFR decreased. Secondly, the relatively small sample size, especially for patients with CKD stage 3, and the number of patients with well-controlled serum mineral electrolytes, hypertension, dyslipidemia and other metabolic abnormalities may have limited our ability to find significant relationships between calcification and these variables. Thirdly, the small number of deaths did not allow an evaluation of mortality. A longer follow-up period is needed to evaluate the prognosis of mild to moderate CKD patients. Fourthly, we were unable to evaluate the effects of confounders such as ethnicity, smoking, arterial stiffness [39] and calcification inhibitors such as fetuin-A [40] . Finally, the measurement of ACI was semi-quantitative, in contrast to quantitative approaches such as electron-beam CT, and techniques using CT have limitations in distinguishing intimal and medial calcification.
In conclusion, decreased GFR may be associated with the presence and extent of abdominal aortic calcification in pre-dialysis CKD stages 3 to 5, and a high level of calcification may be associated with de novo cardiovascular events in pre-dialysis CKD stages 4 and 5. Thus, elucidation of the mechanism through which CKD contributes to vascular calcification may lead to an improved prognosis in this disease.
